Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8630-8641

  Havrylyuk, Dmytro ^a   Zimenkovsky, Borys ^a   Vasylenko, Olexandr ^b   Gzella, Andrzej ^c,d   Lesyk, Roman ^a  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b INSTITUTE OF BIOORGANIC CHEMISTRY AND PETROCHEMISTRY   (Ukraine)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 3 [4 OXO 2 (3 PHENYL 5 THIOPHEN 2 YL 4,5 DIHYDROPYRAZOL 1 YL) 4H THIAZOL 5 YLIDENE] 2,3 DIHYDRO 1H INDOL 2 ONE; 3 [2 [3,5 BIS (4 METHOXYPHENYL) 4,5 DIHYDROPYRAZOL 1 YL] 4 OXO 4,5 DIHYDRO 1,3 THIAZOL 5 YLIDENE] 5 BROMO 2,3 DIHYDRO 1H INDOL 2 ONE; 3 [2 [5 (2 HYDROXYPHENYL) 3 PHENYL 4,5 DIHYDROPYRAZOL 1 YL] 4 OXO 4,5 DIHYDRO 1,3 THIAZOL 5 YLIDENE] 2,3 DIHYDRO 1H INDOL 2 ONE; 3 [3,5 BIS(4 METHOXYPHENYL)PYRAZOL 1 YL] 2,3 DIHYDRO 1H INDOL 2 ONE; 3 [5 (4 METHOXYPHENYL) 3 NAPHTHALEN 2 YLPYRAZOL 1 YL] 2,3 DIHYDRO 1H INDOL 2 ONE; 4 THIAZOLIDINONE DERIVATIVE; 5 BROMO 3 [2 [5 (4 METHOXYPHENYL) 3 NAPHTHALEN 2 YL 4,5 DIHYDROPYRAZOL 1 YL] 4 OXO 4,5 DIHYDRO 1,3 THIAZOL 5 YLIDENE] 2,3 DIHYDRO 1H INDOL 2 ONE; [3 [5 (2 HYDROXYPHENYL) 3 PHENYLPYRAZOL 1 YL] 2 OXO 2,3 DIHYDROINDOL 1 YL]ACETIC ACID; ACODAZOLE; ANTINEOPLASTIC AGENT; AZACITIDINE; BRUCEANTIN; CHROMOMYCIN A3; DACTINOMYCIN; ECHINOMYCIN; ISATIN DERIVATIVE; NITROIMIDAZOLE; PYRAZOLINE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; LEUKEMIA CELL LINE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; ISATIN; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINES;

EID: 84867836493     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300789g     Document Type: Article

References (51)

1. Lesyk, R.; Zimenkovsky, B. 4-Thiazolidones: Centenarian History, Current Status and Perspectives for Modern Organic and Medicinal Chemistry Curr. Org. Chem. 2004, 8, 1547-1577
2. Havrylyuk, D.; Zimenkovsky, B.; Lesyk, R. Synthesis and Anticancer Activity of Novel Nonfused Bicyclic Thiazolidinone Derivatives Phosphorus, Sulfur Silicon Relat. Elem. 2009, 184, 638-650
3. Kaminskyy, D.; Khyluk, D.; Vasylenko, O.; Lesyk, R. An Efficient Method for the Transformation of 5-Ylidenerhodanines into 2,3,5-Trisubstituted-4- thiazolidinones Tetrahedron Lett. 2012, 53, 557-559
4. Kaminskyy, D.; Khyluk, D.; Vasylenko, O.; Zaprutko, L.; Lesyk, R. A Facile Synthesis and Anticancer Activity Evaluation of Spiro[thiazolidinone- isatin] Conjugates Sci. Pharm. 2011, 79, 763-777
5. Lesyk, R. B.; Zimenkovsky, B. S.; Kaminskyy, D. V.; Kryshchyshyn, A. P.; Havrylyuk, D. Ya.; Atamanyuk, D. V.; Subtelna, I. Yu.; Khyluk, D. V. Thiazolidinone Motif in Anticancer Drug Discovery. Experience of DH LNMU Medicinal Chemistry Scientific Group Biopolym. Cell 2011, 27, 107-117
6. Kaminskyy, D.; Zimenkovsky, B.; Lesyk, R. Synthesis and in Vitro Anticancer Activity of 2,4-Azolidinedione-acetic Acids Derivatives Eur. J. Med. Chem. 2009, 44, 3627-3636
7. Kumar, S.; Bawa, S.; Drabu, S; Kumar, R.; Gupta, H. Biological Activities of Pyrazoline Derivatives-A Recent Development Recent Pat. Anti-Infect. Drug Discovery 2009, 4, 154-163
8. Pandeya, S. N.; Smitha, S.; Jyoti, M.; Sridhar, S. K. Biological Activities of Isatin and Its Derivatives Acta Pharm. 2005, 55, 27-46
9. Cutshall, N. S.; ODay, C.; Prezhdo, M. Rhodanine Derivatives as Inhibitors of JSP-1 Bioorg. Med. Chem. Lett. 2005, 15, 3374-3379
10. Carter, P. H.; Scherle, P. A.; Muckelbauer, J. A.; Voss, M. E.; Liu, R.-Q.; Thompson, L. A.; Tebben, A. J.; Solomon, K. A.; Lo, Y. C.; Li, Z.; Strzemienski, P.; Yang, G.; Falahatpisheh, N.; Xu, M.; Wu, Z.; Farrow, N. A.; Ramnarayan, K.; Wang, J.; Rideout, D.; Yalamoori, V.; Domaille, P.; Underwood, D. J.; Trzaskos, J. M.; Friedman, S. M.; Newton, R. C.; Decicco, C. P. Photochemically Enhanced Binding of Small Molecules to the Tumor Necrosis Factor Receptor-1 Inhibits the Binding of TNF-α Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (21) 11879-11884
11. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. Identification of Small-Molecule Inhibitors of Interaction between the BH3 Domain and Bcl-xl Nat. Cell Biol. 2001, 3 (2) 173-182
12. 3 Antagonists as Novel Anticancer Agents J. Med. Chem. 2006, 49, 4526-4534
13. Geronikaki, A.; Eleftheriou, P.; Vicini, P.; Alam, I.; Dixit, A.; Saxena, A. K. 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as New Agents with SHP-2 Inhibitory Action J. Med. Chem. 2008, 51, 5221-5228
14. Ma, J.; Li, S.; Reed, K.; Guo, P.; Gallo, J. M. Pharmacodynamic-Mediated Effects of the Angiogenesis Inhibitor SU5416 on the Tumor Disposition of Temozolomide in Subcutaneous and Intracerebral Glioma Xenograft Models J. Pharmacol. Exp. Ther. 2003, 305, 833-839
15. Lane, M. E.; Yu, B.; Rice, A.; Lipson, K. E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R. G.; Wadler, S. A Novel CDK2-Selective Inhibitor, SU9516, Induces Apoptosis in Colon Carcinoma Cells Cancer Res. 2001, 61, 6170-6177
16. Andreani, A.; Burnelli, S.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Varoli, L.; Landi, L.; Prata, C.; Berridge, M. V.; Grasso, C.; Fiebig, H.-H.; Kelter, G.; Burger, A. M.; Kunkel, M. W. Antitumor Activity of Bis-indole Derivatives J. Med. Chem. 2008, 51, 4563-4570
17. Abdel-Hamid, M.; Abdel-Hafez, A.; El-Koussi, N.; Mahfouz, N.; Innocenti, A.; Supuran, C. T. Design, Synthesis, and Docking Studies of New 1,3,4-Thiadiazole-2-thione Derivatives with Carbonic Anhydrase Inhibitory Activity Bioorg. Med. Chem. 2007, 15, 6975-6984
18. Lin, R.; Chiu, G.; Yu, Y.; Connolly, P. J.; Li, S.; Lu, Y.; Adams, M.; Fuentes-Pesquera, A. R.; Emanuela, S. L.; Greenberger, L. M. Design, Synthesis, and Evaluation of 3,4-Disubstituted Pyrazole Analogues as Anti-tumor CDK Inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 4557-4561
19. Beswick, M. C.; Brough, P. A.; Drysdale, M. J.; Dymock, B. W. 3-(2-Hydroxy-phenyl)-1 H -pyrazole-4-carboxylic Acid Amide Derivatives as HSP90 Inhibitors for the Treatment of Cancer. US 2007/0112192, 2007.
20. Abadi, A. H.; Eissa, A. A. H.; Hassan., G. S. Synthesis of Novel 1,3,4-Trisubstituted Pyrazole Derivatives and Their Evaluation as Antitumor and Antiangiogenic Agents Chem. Pharm. Bull. 2003, 51, 838-844
21. Manna, F.; Chimenti, F.; Fioravantia, R.; Bolasco, A.; Secci, D.; Chimenti, P.; Ferlini, C.; Scambia, G. Synthesis of Some Pyrazole Derivatives and Preliminary Investigation of Their Affinity Binding to P-glycoprotein Bioorg. Med. Chem. Lett. 2005, 15, 4632-4635
22. Solomon, V. R.; Hu, C.; Lee, H. Hybrid Pharmacophore Design and Synthesis of Isatin-Benzothiazole Analogs for Their Anti-Breast Cancer Activity Bioorg. Med. Chem. 2009, 17, 7585-7592
23. Meunier, B. Hybrid Molecules with a Dual Mode of Action: Dream or Reality? Acc. Chem. Res. 2008, 41, 69-77
24. Havrylyuk, D.; Mosula, L.; Zimenkovsky, B.; Vasylenko, O.; Gzella, A.; Lesyk, R. Synthesis and Anticancer Activity Evaluation of 4-Thiazolidinones Containing Benzothiazole Moiety Eur. J. Med. Chem. 2010, 45, 5012-5021
25. Lesyk, R.; Vladzimirska, O.; Holota, S.; Zaprutko, L.; Gzella, A. New 5-substituted Thiazolo[2,3- d ][1,2,4]triazol-6-ones. Synthesis and Anticancer Evaluation Eur. J. Med. Chem. 2007, 42, 641-648
26. Havrylyuk, D.; Kovach, N.; Zimenkovsky, B.; Vasylenko, O.; Lesyk, R. Synthesis and Anticancer Activity of Isatin-Based Pyrazolines and Thiazolidines Conjugates Arch. Pharm. Chem. Life Sci. 2011, 344, 514-522
27. Mosula, L.; Zimenkovsky, B.; Havrylyuk, D.; Missir, A.-V.; Chirita, I. C.; Lesyk, R. Synthesis and Antitumor Activity of Novel 2-Thioxo-4- Thiazolidinones with Benzothiazole Moieties Farmacia 2009, 57, 321-330
28. Kaminskyy, D.; Vasylenko, O.; Atamanyuk, D.; Gzella, A.; Lesyk, R. Isorhodanine and Thiorhodanine Motifs in the Synthesis of Fused Thiopyrano[2,3- d ][1,3]thiazoles Synlett 2011, 10, 1385-1389
29. Havrylyuk, D.; Zimenkovsky, B.; Vasylenko, O.; Zaprutko, L.; Gzella, A.; Lesyk, R. Synthesis of Novel Thiazolone-Based Compounds Containing Pyrazoline Moiety and Evaluation of Their Anticancer Activity Eur. J. Med. Chem. 2009, 44, 1396-1404
30. Havrylyuk, D. Ya.; Zimenkovsky, B. S.; Vasylenko, O. M.; Lesyk, R. B. Synthesis and Evaluation of Antiviral Activity of Thiazolone Derivatives with Pyrazoline Moiety in Molecules J. Org. Pharm. Chem. 2009, 7 (1) 42-47
31. Chem. Abstr. 2009, 151, 491032.
32. Zimenkovsky, B. S.; Devinyak, O. T.; Havrylyuk, D. Ya.; Lesyk, R. B. Analysis of Anticancer Activity of 4-Thiazolidinone Derivatives and Their Classification by Possible Mechanisms of Activity Using Mathematic Modelling Methods J. Org. Pharm. Chem. 2011, 9 (3) 64-71
33. Chem Abstr 2011, 156, 468508.
34. Bergman, J.; Stalhandske, C.; Vallberg, H. Studies of the Reaction between Indole-2,3-diones (Isatins) and Secondary Aliphatic Amines Acta Chem. Scand. 1997, 51, 753-759
35. Desenko, S. M.; Chernenko, V. N.; Orlov, V. D.; Musatov, V. I. 22,-Disubstituted 6,6a-dihydro-1 H -pyrazolo-[1,5- c ]-benzo[ e ]-1,3-oxazines Kharkov Univ. Bull. 2000, 29, 46-49
36. Desenko, S. M.; Chernenko, V. N.; Orlov, V. D.; Musatov, V. I. New Oxidation-Reduction Transformation of Derivatives of 1,10b-Dihydro-1 H -pyrazolo[1,5- c ]-1,3-benzoxazine and 7,12-Dihydro-6 H -[1]benzopyrano[4,3- d ]-1,2,4-triazolo[1,5- a ]pyrimidine Chem. Heterocycl. Compd. 2001, 37, 1312-1313
37. Allen, F. H.; Kennard, O.; Watson, D. G.; Brammer, L.; Orpen, A. G.; Taylor, R. Tables of Bond Lengths Determined by X-ray and Neutron Diffraction. Part 1. Bond Lengths in Organic Compounds J. Chem. Soc. Perkin Trans. 2 1987, S1-19
38. Cremer, D.; Pople, J. A. General definition of ring puckering coordinates J. Am. Chem. Soc. 1975, 97, 1354-1358
39. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines J. Natl. Cancer Inst. 1991, 83 (11) 757-766
40. Boyd, M. R.; Paull, K. D. Some Practical Considerations and Applications of the National Cancer Institute in Vitro Anticancer Drug Discovery Screen Drug Dev. Res. 1995, 34, 91-109
41. Boyd, M. R. The NCI Human Tumour Cell Line (60-Cell): Concept, Implementation, and Applications Screen. In Anticancer Drug Development Guide, 2 nd ed.; Teicher, B. A.; Paul, A. A., Eds.; Humana Press Inc.: Totowa, NJ, 2004; pp 41-62.
42. Shoemaker, R. H. The NCI60 Human Tumour Cell Line Anticancer Drug Screen Nat. Rev. Cancer 2006, 6, 813-823
43. Plowman, J.; Dykes, D. J.; Hollingshead, M.; Simpson-Herren, L.; Alley, M. C.; Human Tumor Xenograft Models in NCI Drug Development. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; Teicher, B., Ed.; Humana Press: Totowa, NJ, 1997; pp 101-125.
44. Hollingshead, M. G.; Alley, M. C.; Camalier, R. F.; Abbott, B. J.; Mayo, J. G.; Malspeis, L.; Grever, M. R. In vivo Cultivation of Tumor Cells in Hollow Fibers Life Sci. 1995, 57, 131-141
45. Paull, K. D.; Lin, C. M.; Malspeis, L.; Hammel, E. Identification of Novel Antimitotic Agents Acting at the Tubulin Level by Computer-Assisted Evaluation of Differential Cytotoxicity Data Cancer Res. 1992, 52, 3892-3900
46. Palaska, E.; Aytemir, V.; Uzbay, I. T.; Erol, D. Synthesis and Antidepressant Activities of Some 3,5-Diphenyl-2-pyrazolines Eur. J. Med. Chem. 2001, 36, 539-543
47. Özdemir, A.; Turan-Zitouni, G.; Kaplancikli, Z. A.; Revial, G.; Güven, K. Synthesis and Antimicrobial Activity of 1-(4-Aryl-2-thiazolyl)-3- (2-thienyl)-5-aryl-2-pyrazoline Derivatives Eur. J. Med. Chem. 2007, 42, 403-409
48. CrysAlis PRO, version 1.171.35.4; Agilent Technologies Ltd. (Oxford Diffraction): Yarnton, U.K., 2009.
49. Sheldrick, G. M. A Short History of SHELX Acta Crystallogr. 2008, A64, 112-122
50. Farrugia, L. J. ORTEP -3 for Windows-A Version of ORTEP-III with a Graphical User Interface (GUI) J. Appl. Crystallogr. 1997, 30, 565
51. CrysAlis PRO, version 1.171.33.41c; Agilent Technologies Ltd. (Oxford Diffraction): Yarnton, U.K., 2009.